(Image source: sheller.com) Shares of Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) are currently up above 8 percent as a result of the FDA allowing its leukemia drug Iclusig to be marketed and distributed to a narrower patient group. Previously, the FDA had suspended sales of the drug because several patients experienced serious complications in clinical studies. According to Marc Courtenay of thestreet.com, “Ariad is now allowed to market Iclusig to chronic myeloid leukemia patients who have the T315i mutation.”